These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 25255239)

  • 1. Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia.
    Hantson P; Lambert C; Hermans C
    Blood Coagul Fibrinolysis; 2015 Mar; 26(2):205-6. PubMed ID: 25255239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: A case report.
    Abouchakra L; Khabbaz Z; Abouassi S; Badaoui G
    J Thorac Cardiovasc Surg; 2015 Aug; 150(2):e19-20. PubMed ID: 26055438
    [No Abstract]   [Full Text] [Related]  

  • 3. Design of the rivaroxaban for heparin-induced thrombocytopenia study.
    Linkins LA; Warkentin TE; Pai M; Shivakumar S; Manji RA; Wells PS; Crowther MA
    J Thromb Thrombolysis; 2014 Nov; 38(4):485-92. PubMed ID: 24549975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia.
    Ng HJ; Than H; Teo EC
    Thromb Res; 2015 Jan; 135(1):205-7. PubMed ID: 24974053
    [No Abstract]   [Full Text] [Related]  

  • 5. Another off-label novel oral anticoagulant to HIT cardiac surgery patients.
    Bianchi CF; Petrucci O
    J Thorac Cardiovasc Surg; 2015 Aug; 150(2):e20-2. PubMed ID: 26048274
    [No Abstract]   [Full Text] [Related]  

  • 6. Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
    Walenga JM; Prechel M; Jeske WP; Hoppensteadt D; Maddineni J; Iqbal O; Messmore HL; Bakhos M
    Br J Haematol; 2008 Oct; 143(1):92-9. PubMed ID: 18671707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban for treatment of HIT: a riveting first experience.
    Linkins LA; Warkentin TE
    Thromb Res; 2015 Jan; 135(1):1-2. PubMed ID: 25466840
    [No Abstract]   [Full Text] [Related]  

  • 8. Rivaroxaban as an Alternative Agent for Heparin-Induced Thrombocytopenia.
    Farasatinasab M; Zarei B; Moghtadaei M; Nasiripour S; Ansarinejad N; Zarei M
    J Clin Pharmacol; 2020 Oct; 60(10):1362-1366. PubMed ID: 32519800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
    Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
    Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of heparin-induced thrombocytopenia with rivaroxaban. Case report].
    Rivera O G; Corsi S O; Pavlovic J A; Aizman S A; Varas A P
    Rev Med Chil; 2017 Sep; 145(9):1213-1217. PubMed ID: 29424412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed-onset heparin-induced thrombocytopenia type-2 during fondiparinux (Arixtra) therapy.
    Modi C; Satani D; Cervellione KL; Cervantes J; Gintautas J
    Proc West Pharmacol Soc; 2009; 52():5-7. PubMed ID: 22128408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban in treatment refractory heparin-induced thrombocytopenia.
    Casan JM; Grigoriadis G; Chan N; Chunilal S
    BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27520997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-induced thrombocytopenia: diagnosis and management.
    Hassell K
    Thromb Res; 2008; 123 Suppl 1():S16-21. PubMed ID: 18829068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Patient who developed heparin-induced thrombocytopenia type II after 24 years on hemodialysis].
    Gavranić BB; Basić-Jukić N; Kes P
    Acta Med Croatica; 2012 Oct; 66 Suppl 2():68-71. PubMed ID: 23513420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study.
    Linkins LA; Warkentin TE; Pai M; Shivakumar S; Manji RA; Wells PS; Wu C; Nazi I; Crowther MA
    J Thromb Haemost; 2016 Jun; 14(6):1206-10. PubMed ID: 27061271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia.
    Bream-Rouwenhorst HR; Hobbs RA
    Pharmacotherapy; 2008 Nov; 28(11):1401-7. PubMed ID: 18957000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The timing of a positive test result for heparin-induced thrombocytopenia relative to the platelet count and anticoagulant therapy in 43 consecutive cases.
    Refaai MA; Van Cott EM; Laposata M
    Am J Clin Pathol; 2003 Apr; 119(4):497-504. PubMed ID: 12710122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment.
    Tvito A; Bakchoul T; Rowe JM; Greinacher A; Ganzel C
    Am J Hematol; 2015 Jul; 90(7):675-8. PubMed ID: 25683147
    [No Abstract]   [Full Text] [Related]  

  • 19. Heparin-induced thrombocytopenia, a prothrombotic disease.
    Levy JH; Hursting MJ
    Hematol Oncol Clin North Am; 2007 Feb; 21(1):65-88. PubMed ID: 17258119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients.
    Cegarra-Sanmartín V; González-Rodríguez R; Paniagua-Iglesias P; Santamaría-Ortiz A; Cueva LF; Galán-Serrano J; Moral-García MV
    J Cardiothorac Vasc Anesth; 2014 Aug; 28(4):1008-12. PubMed ID: 24439171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.